New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
07:41 EDTPRGOPerrigo announces out-licensing of preclinical assets to Imago Pharmaceuticals
Subscribe for More Information
07:17 EDTPRGOLumara Health to be acquired in two separate transactions for $1.11B
Subscribe for More Information
07:11 EDTPRGOPerrigo acquires women's health product portfolio from Lumara for $82M
Subscribe for More Information
06:36 EDTBAXKamada announces second extension of strategic agreement with Baxter
Kamada (KMDA) announced the second extension to supply Glassia to Baxter (BAX) in its strategic agreement with the biopharmaceutical business of Baxter. Through the extended agreement, Kamada secured $26M in additional revenues of Glassia, the company’s proprietary, ready-to-infuse liquid alpha-1 antitrypsin treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency, through 2017. As a result, Kamada expects that total revenue generated through this agreement from October 2010 through end of 2017 will increase to a minimum of $191M compared with a minimum of $110M contained in the original agreement executed in 2010 and a minimum of $165M contained in the May 2013 extension. In addition, the company reports that the supply of Glassia to Baxter has been extended through 2017 and that the transition to royalty payments for Glassia produced by Baxter is not expected to begin before 2018. Until that time, Kamada will continue to produce Glassia for distribution by Baxter. Kamada is confident in its ability to support the increased demand from Baxter throughout the term of the amended agreement.
September 26, 2014
13:53 EDTCVSCVS' Caremark to pay $6M to settle false claims allegations
Subscribe for More Information
09:40 EDTSRDXSurModics upgraded to Buy from Neutral at Sidoti
Subscribe for More Information
05:40 EDTBAXPharmaEngine, Merrimack Pharmaceuticals amend MM-398 license agreement
Subscribe for More Information
September 25, 2014
10:06 EDTCVSCVS Health management to meet with Leerink
Meeting to be held in Los Angeles on October 1 hosted by Leerink.
September 24, 2014
09:05 EDTBAXOn The Fly: Pre-market Movers
Subscribe for More Information
08:33 EDTCVSCVS Health enters into clinical affilitation with three academic medical centers
CVS Health has entered into new clinical affiliations with three leading academic medical centers. The collaborating medical centers include the University of Maryland Medical System, University of Texas Medical Branch at Galveston, and the University of Alabama at Birmingham Health System. Through these clinical affiliations the patients served by these medical centers will continue to have access to clinical support, medication counseling, chronic disease monitoring and wellness programs at CVS/pharmacy stores and MinuteClinic, the retail medical clinic division of CVS Health.
07:39 EDTBAXMerrimack to hold a conference call
Conference call to discuss the exclusive license and collaboration agreement with Baxter International for the development and commercialization of MM-398 also known as "nal-IRI" will be held on September 24 at 8:30 am. Webcast Link
07:06 EDTBAXBaxter, Merrimack enter exclusive ex-U.S. licensing deal for MM-398
Subscribe for More Information
06:14 EDTMDCOThe Medicines Co. to host investor and analyst meeting
Infectious Disease Care Investor and Analyst Meeting will be held on September 24 at 8:30 am. There will be a conference call hookup and webcast available. Webcast Link
September 23, 2014
10:33 EDTCVSCVS Health management to meet with Wolfe Research
Subscribe for More Information
07:04 EDTEBSEmergent BioSolutions initiates study to support licensure of BioThrax
Subscribe for More Information
September 22, 2014
08:30 EDTCYHHospital price targets raised at SunTrust
SunTrust increased its price targets on companies in the hospital space, citing encouraging volume trends shown in a survey. SunTrust raised its price target on Community Health (CYH) to $66 from $55, on HCA Holdings (HCA) to $83 from $75, on LifePoint Hospitals (LPNT) to $80 from $76 and on Tenet (THC) to $68 from $58. SunTrust keeps Buy ratings on Community Health and HCA Holdings, and Neutral ratings on LifePoint and Tenet. It remains upbeat on the sector overall.
September 19, 2014
07:22 EDTCVSNational Press Club holds a luncheon meeting
Subscribe for More Information
06:37 EDTCYHCommunity Health management to meet with SunTrust
Subscribe for More Information
September 18, 2014
11:55 EDTCVSRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
06:46 EDTCYHFTC challenging hospital mergers, NY Times reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use